[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE69227607D1 - Arzneimittel auf Basis von Hyaluronsäure - Google Patents

Arzneimittel auf Basis von Hyaluronsäure

Info

Publication number
DE69227607D1
DE69227607D1 DE69227607T DE69227607T DE69227607D1 DE 69227607 D1 DE69227607 D1 DE 69227607D1 DE 69227607 T DE69227607 T DE 69227607T DE 69227607 T DE69227607 T DE 69227607T DE 69227607 D1 DE69227607 D1 DE 69227607D1
Authority
DE
Germany
Prior art keywords
water
pharmacologically active
hyaluronic acid
soluble
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69227607T
Other languages
English (en)
Other versions
DE69227607T2 (de
Inventor
Yasutaka Igari
Minoru Yamada
Yasuaki Ogawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of DE69227607D1 publication Critical patent/DE69227607D1/de
Publication of DE69227607T2 publication Critical patent/DE69227607T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69227607T 1991-07-10 1992-07-07 Arzneimittel auf Basis von Hyaluronsäure Expired - Fee Related DE69227607T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP17020591 1991-07-10

Publications (2)

Publication Number Publication Date
DE69227607D1 true DE69227607D1 (de) 1998-12-24
DE69227607T2 DE69227607T2 (de) 1999-04-15

Family

ID=15900617

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69227607T Expired - Fee Related DE69227607T2 (de) 1991-07-10 1992-07-07 Arzneimittel auf Basis von Hyaluronsäure

Country Status (4)

Country Link
EP (1) EP0522491B1 (de)
AT (1) ATE173405T1 (de)
CA (1) CA2073554C (de)
DE (1) DE69227607T2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074512A (en) * 1991-06-27 2000-06-13 Applied Materials, Inc. Inductively coupled RF plasma reactor having an overhead solenoidal antenna and modular confinement magnet liners
SE9400036D0 (sv) * 1994-01-10 1994-01-10 Pharmacia Ab Low modecular weight hyaluronic acid
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US5858477A (en) 1996-12-10 1999-01-12 Akashic Memories Corporation Method for producing recording media having protective overcoats of highly tetrahedral amorphous carbon
SE9904121D0 (sv) 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
JP2002003398A (ja) * 2000-04-17 2002-01-09 Ltt Institute Co Ltd 徐放製剤、その製造法及びワクチン
DE10064219B9 (de) * 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease

Also Published As

Publication number Publication date
CA2073554C (en) 2003-06-10
DE69227607T2 (de) 1999-04-15
ATE173405T1 (de) 1998-12-15
CA2073554A1 (en) 1993-01-11
EP0522491A1 (de) 1993-01-13
EP0522491B1 (de) 1998-11-18

Similar Documents

Publication Publication Date Title
DE3787460T2 (de) Schimärische peptide für die lieferung von neuropeptiden durch die blut-hirn-grenze.
DE69434963D1 (de) Selektiv auf die leber wirkende pharmazeutisch aktive substanz
ATE189772T1 (de) Unter wärmeeinwirkung reversibel gelierende medizinische zusammensetzung auf wasserbasis
ATE74519T1 (de) Waessrige loesung von fettloeslichen wirkstoffen.
DE69428040D1 (de) Orale darreichungsform
NO904378L (no) Fremgangsmaate for fremstilling av et modifisert protein for terapeutisk anvendelse.
SE8902638L (sv) Stabiliserade protein- eller peptidkonjugat
CY1114000T1 (el) Σταθεροποιημενα διαλυματα τεριπαρατιδης
ATE185268T1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
CY1110078T1 (el) Παρασκευασματα με ιωδιουχο ποβιδονη για την αγωγη τραυματων
DE69322251D1 (de) Medizinische zusammensetzung
DE69227607D1 (de) Arzneimittel auf Basis von Hyaluronsäure
DE60018409D1 (de) Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren
WO1999053944A1 (es) Metodo para el tratamiento del 'shock' endotoxico en mamiferos
DK0559145T3 (da) Lægemiddel til truende abort
ATE311897T1 (de) Behandlung von multiplersklerose mit einer kombination von interferon und wachstumshormone
ES2182840T3 (es) Factor xiii para el tratamiento de heridas de la piel.
DE3781682D1 (de) Verbesserungen im gebrauch oder in bezug auf den gebrauch von egf.
EP0582932A1 (de) Therapeutisches System zur parenteralen Verabreichung von hämatopoetischen Wachstumsfaktoren
KR890001555A (ko) 요산 배설용 조성물
IL110888A0 (en) Pharmaceutical compositions for the treatment of liver diseases comprising a benzothiazepine derivative
RU93052444A (ru) Лекарственный препарат бан
RU98109592A (ru) Применение белка s-100b в лекарственных средствах и лекарственные средства, содержащие белок s-100b
RU94013606A (ru) Гемостимулятор
KR900701307A (ko) 항 비루스성 또는 항 박테리아성 화합물과 그 사용방법

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: TAKEDA PHARMACEUTICAL CO. LTD., OSAKA, JP

8339 Ceased/non-payment of the annual fee